“Moderna” stock decline despite achieving strong revenues in the second quarter

“Moderna” shares declined during Wednesday’s trading, despite achieving strong revenue during the second quarter, supported by the experiences of its promising vaccine to prevent corona infection.

“Moderna” reported quarterly revenue of $ 66.4 million in the second quarter, compared to expectations that indicated $ 27.4 million in revenue and after revenue in the same period in 2019 at $ 13.1 million.

The American Drug and Biotechnology Company reported a quarterly loss of $ 116.7 million, or 31 cents a share, in the second quarter, compared to a loss of $ 134.9 million, or 41 cents per share, in the same period last year.

“Moderna” reported on Wednesday that it had set the price of its promising anti-Corona vaccine at between $ 32 and $ 37 per dose for some clients.

During trading session, the price of “Moderna” stock fell by 3.4% and closed the session at $ 75.8, and recorded the highest price at $ 77.4, while the lowest price was recorded at $ 73.6.